Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) CFO Thomas Patrick Kelly sold 4,359 shares of Deciphera Pharmaceuticals stock in a transaction dated Friday, January 3rd. The stock was sold at an average price of $57.35, for a total transaction of $249,988.65. Following the sale, the chief financial officer now owns 7,641 shares of the company’s stock, valued at $438,211.35. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
Thomas Patrick Kelly also recently made the following trade(s):
- On Monday, October 28th, Thomas Patrick Kelly sold 3,750 shares of Deciphera Pharmaceuticals stock. The shares were sold at an average price of $44.34, for a total transaction of $166,275.00.
Shares of DCPH traded up $1.35 during mid-day trading on Thursday, hitting $66.73. The company’s stock had a trading volume of 3,343 shares, compared to its average volume of 583,825. Deciphera Pharmaceuticals Inc has a one year low of $19.88 and a one year high of $70.00. The firm has a market capitalization of $3.17 billion, a PE ratio of -23.52 and a beta of 2.03. The stock’s 50-day moving average is $59.65 and its two-hundred day moving average is $40.10.
Deciphera Pharmaceuticals (NASDAQ:DCPH) last posted its quarterly earnings data on Monday, November 4th. The company reported ($1.28) earnings per share for the quarter, missing the consensus estimate of ($1.19) by ($0.09). Research analysts expect that Deciphera Pharmaceuticals Inc will post -4.11 earnings per share for the current fiscal year.
A number of hedge funds have recently modified their holdings of DCPH. Bank of America Corp DE raised its stake in Deciphera Pharmaceuticals by 4.2% during the second quarter. Bank of America Corp DE now owns 26,052 shares of the company’s stock worth $588,000 after acquiring an additional 1,062 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Deciphera Pharmaceuticals by 162.0% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,737 shares of the company’s stock valued at $59,000 after buying an additional 1,074 shares in the last quarter. Bank of Montreal Can acquired a new stake in shares of Deciphera Pharmaceuticals in the second quarter valued at $28,000. Virtus ETF Advisers LLC increased its stake in shares of Deciphera Pharmaceuticals by 17.7% in the second quarter. Virtus ETF Advisers LLC now owns 12,449 shares of the company’s stock valued at $281,000 after buying an additional 1,871 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its stake in shares of Deciphera Pharmaceuticals by 89.2% in the second quarter. JPMorgan Chase & Co. now owns 4,057 shares of the company’s stock valued at $95,000 after buying an additional 1,913 shares in the last quarter. 69.45% of the stock is owned by hedge funds and other institutional investors.
A number of brokerages have recently weighed in on DCPH. SunTrust Banks began coverage on Deciphera Pharmaceuticals in a report on Friday, January 10th. They issued a “buy” rating and a $77.00 target price on the stock. JMP Securities reiterated a “buy” rating and issued a $70.00 target price on shares of Deciphera Pharmaceuticals in a report on Wednesday. ValuEngine downgraded Deciphera Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, October 19th. Zacks Investment Research downgraded Deciphera Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, November 7th. Finally, HC Wainwright began coverage on Deciphera Pharmaceuticals in a report on Thursday, October 3rd. They issued a “buy” rating and a $60.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and ten have given a buy rating to the stock. Deciphera Pharmaceuticals has an average rating of “Buy” and a consensus price target of $57.50.
Deciphera Pharmaceuticals Company Profile
Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, melanoma, NSCLC/germ cell/penile, and soft tissue sarcomas.
Featured Story: 52-Week High/Low Prices For Stock Selection
Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.